BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 530 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
|Montanaro Asset Management Ltd||387,800||$28,770,882||4.47%|
|Brown Capital Management||3,262,377||$242,035,750||3.62%|
|Sandhill Capital Partners LLC||501,059||$37,173,549||3.56%|
|STONE RUN CAPITAL, LLC||89,435||$6,635,183||3.17%|
|DF DENT & CO INC||2,949,044||$218,789,610||3.08%|
|Ownership Capital B.V.||2,324,358||$172,444,120||3.03%|
|Jackson Square Partners, LLC||1,485,067||$110,177,121||2.98%|
|Summit Creek Advisors LLC||283,412||$21,026,336||2.74%|
|Spence Asset Management||111,666||$8,284,501||2.65%|
|MAIRS & POWER INC||3,025,978||$224,497,293||2.59%|
|Pembroke Management, LTD||305,005||$22,628,321||2.47%|
|AMERICAN CAPITAL MANAGEMENT INC||886,827||$65,793,695||2.32%|
|Aristotle Atlantic Partners, LLC||523,186||$38,815,170||2.00%|
|GENEVA CAPITAL MANAGEMENT LLC||1,070,257||$79,402,344||1.62%|
|Select Equity Group, L.P.||5,640,897||$418,498,148||1.49%|
|Eversept Partners, LP||188,659||$13,996,611||1.22%|
|BAMCO INC /NY/||5,379,492||$399,104,511||1.20%|
|Dorsey & Whitney Trust CO LLC||142,838||$10,597,152||0.96%|
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
This page lists BIO-TECHNE CORP's shareholders in Q1 2023. To view BIO-TECHNE CORP's shareholder history, click here.